Platelet-Rich Plasma in Management of Tendinopathy | ||||
| Benha Journal of Applied Sciences | ||||
| Article 45, Volume 5, Issue 8 part (1) - (2), December 2020, Page 279-286 PDF (566.63 K) | ||||
| Document Type: Original Research Papers | ||||
| DOI: 10.21608/bjas.2020.187227 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| H.H. Ahmed; E.M. Mohammady; M.M. Lotfy | ||||
| Orthopedic Surgery Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
| Abstract | ||||
| Tendons are vital component of our musculoskeletal system that link between the dynamic and the static part transmitting the forces generated by muscles to bony attachments producing joint motion and stabilize joints. Chronic painful tendon disorders are common in athletic and sedentary individuals. Tendon degeneration may occur when tissue breakdown exceeds the rate of tissue healing due to extrinsic factors such as tendon overload, excessive mechanical stimulation, training errors, fatigue or chemical stresses. Choices of treatment often change in parallel with physiopathological discoveries regarding tendinopathy. Platelets Riched plasma (PRP) is defined as a volume of the plasma fraction of autologous blood having a platelet concentration of 5 times more than base line. Injection of platelet-rich plasma (PRP) is considered a promising new treatment in management of tendinopathy. Platelet-rich plasma (PRP) injections are widely accepted by patients because the injection is produced from the patient’s own blood and the risk of adverse effects is minimal. The aim of this Syistimic Review is to highlight on the recent trends in management of tendinopathy, especially platelet rich plasma. | ||||
| Keywords | ||||
| Musculotendinous unit; Tendinopathy; Platelet rich plasma | ||||
|
Statistics Article View: 115 PDF Download: 230 |
||||
